PL3038643T3 - Przeciwciała przeciwko csf-1r - Google Patents

Przeciwciała przeciwko csf-1r

Info

Publication number: PL3038643T3
Authority: PL; Poland
Prior art keywords: antibodies against; against csf; csf; antibodies
Prior art date: 2013-08-30

Application number

PL14755668T

Other languages

English (en)

Inventor

Graham Craggs

Karine Jeannine Madeleine Hervé

Diane Marshall

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-30

Filing date

2014-08-26

Publication date

2019-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3038643(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-26 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2019-11-29 Publication of PL3038643T3 publication Critical patent/PL3038643T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)

PL14755668T 2013-08-30 2014-08-26 Przeciwciała przeciwko csf-1r PL3038643T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1315487.7A GB201315487D0 (en)	2013-08-30	2013-08-30	Antibodies
PCT/EP2014/068050 WO2015028455A1 (en)	2013-08-30	2014-08-26	Antibodies
EP14755668.2A EP3038643B1 (en)	2013-08-30	2014-08-26	Antibodies against csf-1r

Publications (1)

Publication Number	Publication Date
PL3038643T3 true PL3038643T3 (pl)	2019-11-29

Family

ID=49397073

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL14755668T PL3038643T3 (pl)	2013-08-30	2014-08-26	Przeciwciała przeciwko csf-1r
PL19171833.7T PL3549599T3 (pl)	2013-08-30	2014-08-26	Przeciwciała przeciwko csf-1r

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL19171833.7T PL3549599T3 (pl)	2013-08-30	2014-08-26	Przeciwciała przeciwko csf-1r

Country Status (39)

Country	Link
US (2)	US9908939B2 (pl)
EP (3)	EP4282881A3 (pl)
JP (3)	JP6632075B2 (pl)
KR (1)	KR102303130B1 (pl)
CN (2)	CN112321711B (pl)
AR (1)	AR097464A1 (pl)
AU (1)	AU2014314304B2 (pl)
BR (1)	BR112016004324B1 (pl)
CA (1)	CA2922240C (pl)
CL (1)	CL2016000438A1 (pl)
CY (1)	CY1121964T1 (pl)
DK (2)	DK3549599T5 (pl)
EA (1)	EA036255B1 (pl)
ES (2)	ES2965207T3 (pl)
FI (1)	FI3549599T3 (pl)
GB (1)	GB201315487D0 (pl)
HR (2)	HRP20231264T1 (pl)
HU (2)	HUE064437T2 (pl)
IL (1)	IL244043B (pl)
LT (2)	LT3549599T (pl)
MA (2)	MA44922B1 (pl)
MX (1)	MX372950B (pl)
MY (1)	MY172484A (pl)
NZ (1)	NZ717399A (pl)
PE (2)	PE20160528A1 (pl)
PH (1)	PH12016500275B1 (pl)
PL (2)	PL3038643T3 (pl)
PT (2)	PT3549599T (pl)
RS (2)	RS64784B1 (pl)
SG (1)	SG11201601151PA (pl)
SI (2)	SI3038643T1 (pl)
SM (2)	SMT202300409T1 (pl)
TN (1)	TN2016000067A1 (pl)
TR (1)	TR201909478T4 (pl)
TW (1)	TWI531582B (pl)
UA (1)	UA118354C2 (pl)
UY (1)	UY35718A (pl)
WO (1)	WO2015028455A1 (pl)
ZA (1)	ZA201601437B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
US10316097B2 (en) *	2015-05-27	2019-06-11	Ucb Biopharma Sprl	Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
CN107810012A (zh) *	2015-06-02	2018-03-16	豪夫迈·罗氏有限公司	使用抗il‑34抗体治疗神经疾病的组合物和方法
CN116903741A (zh)	2016-06-20	2023-10-20	科马布有限公司	特异性结合于pd-l1的抗体或其抗原结合片段及其用途
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CN111278459A (zh) *	2017-05-19	2020-06-12	赛达克斯制药股份有限公司	组合疗法
GB201803226D0 (en)	2018-02-28	2018-04-11	Ultrahuman Twelve Ltd	CSF1R Binding agents
CN108948198B (zh) *	2018-07-18	2020-09-01	博奥信生物技术（南京）有限公司	抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) *	2018-07-18	2019-04-16	博奥信生物技术（南京）有限公司	一种抗人csf-1r单克隆抗体及应用
WO2020124039A1 (en) *	2018-12-13	2020-06-18	Development Center For Biotechnology	Anti-human csf-1r antibody and uses thereof
CN113939539B (zh) *	2019-05-15	2024-06-04	博奥信生物技术（南京）有限公司	结合csf-1r的抗体及其用途
WO2021119128A1 (en) *	2019-12-09	2021-06-17	Syndax Pharmaceuticals, Inc.	Antibodies for the treatment of chronic graft versus host disease
US20230203170A1 (en) *	2019-12-24	2023-06-29	Adagene (Suzhou) Limited	Anti-CSF1R Molecules and Use Thereof
TW202446418A (zh)	2023-05-17	2024-12-01	美商錫達斯醫藥股份有限公司	使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法
TW202519258A (zh)	2023-07-23	2025-05-16	美商英塞特公司	使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病之方法
US20250325664A1 (en)	2024-04-22	2025-10-23	Incyte Corporation	Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
ES2374068T3 (es)	2002-12-03	2012-02-13	Ucb Pharma, S.A.	Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
PL1644412T5 (pl)	2003-07-01	2019-01-31	Ucb Biopharma Sprl	Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) *	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
MY146381A (en) *	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
DK2188313T3 (en) *	2007-08-21	2017-12-11	Amgen Inc	HUMAN C-FMS ANTI-BINDING PROTEINS
EP2535351A3 (en)	2007-09-26	2013-04-03	UCB Pharma S.A.	Dual specificity antibody fusions
JO3240B1 (ar) *	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
BRPI0909044B8 (pt)	2008-03-14	2021-05-25	Transgene Sa	anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
US8470977B2 (en) *	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
EA201100527A1 (ru)	2008-09-26	2011-10-31	Юсб Фарма С.А.	Биологические продукты
US20120283415A1 (en)	2009-09-10	2012-11-08	Ucb Pharma S.A.	Multivalent Antibodies
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
HUE026201T2 (en) *	2009-12-10	2016-05-30	Hoffmann La Roche	Antibodies binding to human CSF1R extracellular domain 4 and their use
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
WO2011131407A1 (en)	2010-03-05	2011-10-27	F. Hoffmann-La Roche Ag	Antibodies against human csf-1r and uses thereof
RU2617971C2 (ru)	2010-03-05	2017-04-28	Ф.Хоффманн-Ля Рош Аг	Антитела против csf-1r человека и их применение
AR080698A1 (es) *	2010-04-01	2012-05-02	Imclone Llc	Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) *	2010-05-04	2019-02-22	Five Prime Therapeutics, Inc.	Protutijela koja se vežu na csf1r
US10023643B2 (en)	2011-12-15	2018-07-17	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R and uses thereof
GB201315486D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies

2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-26 SM SM20230409T patent/SMT202300409T1/it unknown
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active Active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 CN CN202011009068.8A patent/CN112321711B/zh active Active
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 DK DK19171833.7T patent/DK3549599T5/da active
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 SM SM20190471T patent/SMT201900471T1/it unknown
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 MX MX2016002166A patent/MX372950B/es active IP Right Grant
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en not_active Ceased
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es active IP Right Grant
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275B1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
2019
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending

Also Published As

Publication number	Publication date
HRP20191051T1 (hr)	2019-09-06
PT3038643T (pt)	2019-07-25
US10421814B2 (en)	2019-09-24
GB201315487D0 (en)	2013-10-16
CN112321711B (zh)	2024-11-08
CN112321711A (zh)	2021-02-05
MX2016002166A (es)	2016-06-23
PE20160528A1 (es)	2016-05-21
HRP20231264T1 (hr)	2024-02-02
MA44922A1 (fr)	2019-08-30
CA2922240C (en)	2023-09-05
TWI531582B (zh)	2016-05-01
CA2922240A1 (en)	2015-03-05
US20180162947A1 (en)	2018-06-14
EP3038643B1 (en)	2019-05-01
UY35718A (es)	2015-03-27
RS59019B1 (sr)	2019-08-30
JP2022002523A (ja)	2022-01-11
CL2016000438A1 (es)	2016-11-11
IL244043A0 (en)	2016-04-21
SMT202300409T1 (it)	2024-01-10
IL244043B (en)	2021-01-31
MX372950B (es)	2020-04-03
EP3549599A1 (en)	2019-10-09
PH12016500275A1 (en)	2016-05-02
NZ717399A (en)	2021-12-24
HK1220142A1 (en)	2017-04-28
UA118354C2 (uk)	2019-01-10
FI3549599T3 (fi)	2023-10-31
TN2016000067A1 (en)	2017-07-05
PT3549599T (pt)	2023-11-21
LT3038643T (lt)	2019-07-25
JP2016529266A (ja)	2016-09-23
BR112016004324B1 (pt)	2024-01-16
US20160200821A1 (en)	2016-07-14
JP7195237B2 (ja)	2022-12-23
PH12016500275B1 (en)	2019-11-29
EP4282881A3 (en)	2024-02-21
EP3038643A1 (en)	2016-07-06
SG11201601151PA (en)	2016-03-30
AU2014314304B2 (en)	2019-12-05
DK3038643T3 (da)	2019-06-24
PL3549599T3 (pl)	2024-03-04
TW201512221A (zh)	2015-04-01
MA38930A1 (fr)	2017-12-29
TR201909478T4 (tr)	2019-07-22
KR20160044018A (ko)	2016-04-22
ES2733735T3 (es)	2019-12-02
US9908939B2 (en)	2018-03-06
JP6632075B2 (ja)	2020-01-15
ES2965207T3 (es)	2024-04-11
AU2014314304A1 (en)	2016-03-17
MA44922B1 (fr)	2020-06-30
EA036255B1 (ru)	2020-10-20
PE20201067A1 (es)	2020-10-19
DK3549599T3 (en)	2023-10-30
BR112016004324A2 (pt)	2017-10-24
RS64784B1 (sr)	2023-11-30
CN105658236B (zh)	2021-03-19
SI3549599T1 (sl)	2023-12-29
HUE045672T2 (hu)	2020-01-28
ZA201601437B (en)	2018-08-29
CY1121964T1 (el)	2020-10-14
MY172484A (en)	2019-11-26
EA201690503A1 (ru)	2016-06-30
HUE064437T2 (hu)	2024-03-28
AR097464A1 (es)	2016-03-16
CN105658236A (zh)	2016-06-08
JP2020005652A (ja)	2020-01-16
LT3549599T (lt)	2023-11-10
SMT201900471T1 (it)	2019-09-09
EP3549599B1 (en)	2023-09-06
SI3038643T1 (sl)	2019-08-30
DK3549599T5 (da)	2024-09-02
EP4282881A2 (en)	2023-11-29
WO2015028455A1 (en)	2015-03-05
KR102303130B1 (ko)	2021-09-16

Publication	Publication Date	Title
IL269528A (en)	2019-11-28	Anti- FCRH5 antibodies
SG11201509361TA (en)	2015-12-30	Novel antibodies
GB201322583D0 (en)	2014-02-05	Antibodies
LT3038643T (lt)	2019-07-25	Antikūnai prieš csf-1r
ZA201506568B (en)	2017-11-29	Anti-tnf-anti-il-17 bispecific antibodies
HRP20190502T1 (hr)	2019-05-03	Afukozilirana anti-fgfr2iiib protutijela
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201312133D0 (en)	2013-08-21	Immunotherapy
GB201300706D0 (en)	2013-02-27	Antibody
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
GB201312226D0 (en)	2013-08-21	Improved antibodies
SG11201604503XA (en)	2016-07-28	Cytotoxic antibody
GB201318283D0 (en)	2013-11-27	Antibodies